— Know what they know.
Not Investment Advice

CRL NYSE

Charles River Laboratories International, Inc.
1W: -0.2% 1M: -14.1% 3M: -6.0% YTD: -21.5% 1Y: +10.7% 3Y: -15.6% 5Y: -51.7%
$160.30
+1.44 (+0.91%)
After Hours: $156.45 (-3.85, -2.40%)
Weekly Expected Move ±8.0%
$127 $139 $151 $163 $175
NYSE · Healthcare · Medical - Diagnostics & Research · Alpha Radar Strong Sell · Power 33 · $7.7B mcap · 48M float · 1.91% daily turnover · Short 71% of daily vol

Cash Flow Trends

Operating Cash Flow
$738M +0.4% ▲
5Y CAGR: +6.2%
Capital Expenditures
$219M +5.9% ▲
5Y CAGR: +5.6%
Free Cash Flow
$518M +3.4% ▲
5Y CAGR: +6.4%
Dividends Paid
$0 +0.0% ▲
Buybacks
$361M -202.6% ▼
Net Change in Cash
$10M +113.2% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income$399M$493M$480M$25M-$142M
Depreciation & Amort.$266M$304M$314M$362M$403M
Stock-Based Comp.$71M$74M$72M$70M$71M
Change in Working Capital$43M-$153M-$102M-$30M$14M
Other Non-Cash Items$6M-$62M-$29M$375M$467M
Operating Cash Flow$761M$620M$684M$735M$738M
— Investing Activities —
Capital Expenditures-$229M-$325M-$319M-$233M-$219M
Acquisitions (Net)-$1.2B-$120M-$195M-$5M$0
Investment Purchases-$46M-$158M-$54M-$53M-$20M
Investment Sales$7M$5M$7M$42M$9M
Other Investing$264K-$9M-$2M$5M$21M
Investing Cash Flow-$1.4B-$608M-$563M-$245M-$209M
— Financing Activities —
Net Debt Issuance$670M$20M-$75M-$412M-$122M
Stock Repurchased-$41M-$39M-$24M-$119M-$361M
Dividends Paid$0$0$0$0$0
Other Financing$43M-$24M$14M-$20M-$55M
Financing Cash Flow$673M-$42M-$86M-$551M-$537M
Net Change in Cash$13M-$5M$43M-$79M$10M
Cash End of Period$246M$241M$284M$206M$216M
Free Cash Flow$532M$295M$365M$502M$518M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms